Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 6, 2003, Pages 651-658

  Amos, Gregory J ^a   Jacobson, Ingemar ^a   Duker, Göran ^a   Carlsson, Leif ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Class III antiarrhythmic drug; HERG; Human; Potassium channel; Proarrhythmia

Indexed keywords

ALMOKALANT; DOFETILIDE;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; FIBROBLAST; GENE; GENETIC TRANSFECTION; HUMAN ETHER A GO GO RELATED GENE; IC 50; KINETICS; MEMBRANE CURRENT; MOUSE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; REPOLARIZATION;

ACTION POTENTIALS; ALKANES; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BICYCLO COMPOUNDS; BINDING, COMPETITIVE; CATION TRANSPORT PROTEINS; CELL LINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FIBROBLASTS; HEART; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIALS; MICE; MODELS, ANIMAL; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PREDICTIVE VALUE OF TESTS; PROPANOLAMINES; SULFONAMIDES; TIME FACTORS; TRANS-ACTIVATORS;

EID: 0038307007     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.02554.x     Document Type: Article

References (29)

1. Nattel S, Singh BN: Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III actions. Am J Cardiol 1999;84(9A):11R-19R.
2. Foster RH, Wilde ML Markham A: Ibutilide: A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997;54:312-330.
3. Falk RH, DeCara JM: Dofetilide: A new pure class III antiarrhythmic agent. Am Heart J 2000;140:696-706.
4. Amos GJ, Abrahamsson C, Duker G, Hondeghem L, Palmer M, Carlsson L: Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52. Implications for proarrhythmic potential. Cardiovasc Res 2001;49:351-360.
5. Ohler A, Ravens U: Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther 1994;270:460-465.
6. Wang Z, Fermini B, Nattel S: Rapid and slow co mponents of delayed rectifier current in human atrial myocytes. Cardiovasc Res 1994;28:1540-1546.
7. Veldkamp MW, van Ginneken ACG, Opthof T, Bouman LN: Delayed rectifier channels in human ventricular myocytes. Circulation 1995;92:3497-3504.
8. + current in human ventricular myocytes. Circ Res 1996;78:689-696.
9. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993;73:379-385.
10. Firek L, Giles WR: Outward currents underlying repolarization in human atrial myocytes. Cardiovasc Res 1995;30:31-38.
11. + currents in nonfailing human hearts. Similarities between right septal subendocardial and left subepicardial ventricular myocytes. Circulation 1995;92:1179-1187.
12. Amos GJ, Wettwer E, Metzger F, Li Q, Himmel HM, Ravens U: Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 1996;491:31-50.
13. Yue L, Feng J, Li G-R, Nattel S: Transient outward and delayed rectifier currents in canine atrium: Properties and role of isolation methods. Am J Physiol 1996;270:H2157-H2168.
14. + channels: Friend and foe. TIPS 2001;22:240-246.
15. Snyders DJ, Chaudhary A: High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 1996;49:949-955.
16. Weerapura M, Nattel S, Chattier D, Caballero R, Herbert TE: A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native delayed rectifier current. Is MiRP1 the missing link? J Physiol (Lond) 2002;540:15-27.
17. Courtemanche M, Ramirez RJ, Nattel S: Ionic mechanisms underlying human atrial action potential properties: Insights from a mathematical model. Am J Physiol 1998;275:H301-H321.
18. Ks contributes to the longer action potential of the M cell. Circ Res 1995;76:351-365.
19. Wang S, Liu S, Morales JM, Strauss HC, Rasmusson RL: A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes. J Physiol 1997;502:45-60.
20. Hines M, Carnevale NT: The NEURON simulation environment. Neural Comput 1997;9:1179-1209.
21. + channel. Circ Res 1993;72:707-714.
22. 3H]Dofetilide binding: Biological models that manifest solely the high or the low affinity binding site. J Mol Cell Cardiol 1996;28:1085-1096.
23. + current in cardiac myocytes by dofetilide. J Pbarmacol Exp Ther 1992;262:809-817.
24. Noble D, Varghese A, Kohl P, Noble P: Improved guinea-pig ventricular cell model incorporating a diadic space, Ikr and Iks, and length- and tension-dependent processes. Can J Cardiol 1998;14:123-134.
25. Hancox JC, Levi AJ, Witchel HK: Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential. Pflügers Arch Eur J Physiol 1998;436:843-853.
26. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-68.
27. Walker BD, Singleton CB, Tie H, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, Campbell TJ: Comparative effects of azimilide and ambasilide on the human ether-a-go-go related gene (HERG) potassium channel. Cardiovasc Res 2000;48:44-58.
28. Hondeghem LM, Carlsson L, Duker G: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic, Circulation 2001;103:2004-2013.
29. Antzelevitch C, Sicouri S: Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsades de pointes. J Am roll Cardiol 1994;23:259-277.